GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OTCPK:GNMSF) » Definitions » Cash Ratio

GNMSF (Genmab AS) Cash Ratio : 3.98 (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Genmab AS Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Genmab AS's Cash Ratio for the quarter that ended in Dec. 2024 was 3.98.

Genmab AS has a Cash Ratio of 3.98. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Genmab AS's Cash Ratio or its related term are showing as below:

GNMSF' s Cash Ratio Range Over the Past 10 Years
Min: 3.98   Med: 11.98   Max: 16.58
Current: 3.98

During the past 13 years, Genmab AS's highest Cash Ratio was 16.58. The lowest was 3.98. And the median was 11.98.

GNMSF's Cash Ratio is ranked better than
60.34% of 1470 companies
in the Biotechnology industry
Industry Median: 2.665 vs GNMSF: 3.98

Genmab AS Cash Ratio Historical Data

The historical data trend for Genmab AS's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Cash Ratio Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.83 12.33 12.25 11.33 3.98

Genmab AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.33 10.72 3.61 3.78 3.98

Competitive Comparison of Genmab AS's Cash Ratio

For the Biotechnology subindustry, Genmab AS's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cash Ratio falls into.



Genmab AS Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Genmab AS's Cash Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash Ratio (A: Dec. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=2962.75/745.286
=3.98

Genmab AS's Cash Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash Ratio (Q: Dec. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=2962.75/745.286
=3.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS  (OTCPK:GNMSF) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Genmab AS Cash Ratio Related Terms

Thank you for viewing the detailed overview of Genmab AS's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.